Cargando…

Engineered FGF19(ΔKLB) protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model

BACKGROUND: The major safety concern of the clinical application of wild type FGF19 (FGF19(WT)) emerges given that its extended treatment causes hepatocellular carcinoma. Therefore, we previously generated a safer FGF19 variant - FGF19(ΔKLB), which have same effects on glycemic control and bile acid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Lu, Zhao, Tiantian, Huang, Lei, Pan, Xiaomin, Wu, Tianzhen, Feng, Xin, Chen, Taoli, Wu, Jiamin, Niu, Jianlou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548598/ https://www.ncbi.nlm.nih.gov/pubmed/37789318 http://dx.doi.org/10.1186/s12896-023-00810-9

Ejemplares similares

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity
por: Agrawal, Archita, et al.
Publicado: (2018)

Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB
por: Yang, Chaofeng, et al.
Publicado: (2012)

Mechanism of Paeoniflorin on ANIT-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology
por: Chen, Lisheng, et al.
Publicado: (2021)

Mechanism of crocin I on ANIT-induced intrahepatic cholestasis by combined metabolomics and transcriptomics
por: Song, Dandan, et al.
Publicado: (2023)

Dioscin Protects ANIT-Induced Intrahepatic Cholestasis Through Regulating Transporters, Apoptosis and Oxidative Stress
por: Yao, Hong, et al.
Publicado: (2017)

Paeoniflorin Protects against ANIT-Induced Cholestatic Liver Injury in Rats via the Activation of SIRT1-FXR Signaling Pathway
por: Chen, Lisheng, et al.
Publicado: (2021)

Effect of Different Ratios of Yinchen and Gancao Decoction on ANIT-Treated Cholestatic Liver Injury in Mice and Its Potential Underlying Mechanism
por: Su, Huizong, et al.
Publicado: (2021)

Quercetin 7-rhamnoside protects against alpha-naphthylisothiocyanate (ANIT)-induced in cholestatic hepatitis rats by improving biliary excretion and inhibiting inflammatory responses
por: Jin, Hong-Liu, et al.
Publicado: (2023)

A Network Pharmacology Study of the Molecular Mechanisms of Hypericum japonicum in the Treatment of Cholestatic Hepatitis with Validation in an Alpha-Naphthylisothiocyanate (ANIT) Hepatotoxicity Rat Model
por: Feng, Sen Ling, et al.
Publicado: (2021)

KLB, encoding β‐Klotho, is mutated in patients with congenital hypogonadotropic hypogonadism
por: Xu, Cheng, et al.
Publicado: (2017)

KLB dysregulation mediates disrupted muscle development in intrauterine growth restriction
por: Cortes‐Araya, Yennifer, et al.
Publicado: (2022)

FGF23(C-tail) improves diabetic nephropathy by attenuating renal fibrosis and inflammation
por: Zhang, Xiaomin, et al.
Publicado: (2018)

Glucagon receptor signaling regulates weight loss via central KLB receptor complexes
por: Nason, Shelly R., et al.
Publicado: (2021)

Predicting Target Genes of San-Huang-Chai-Zhu Formula in Treating ANIT-Induced Acute Intrahepatic Cholestasis Rat Model via Bioinformatics Analysis Combined with Experimental Validation
por: Yao, Jiaming, et al.
Publicado: (2021)

SRT1720 Alleviates ANIT-Induced Cholestasis in a Mouse Model
por: Yu, Linxi, et al.
Publicado: (2017)

KLB gene polymorphism is associated with obesity and non-alcoholic fatty liver disease in the Han Chinese
por: Ji, Fang, et al.
Publicado: (2019)

Curcumin protects ANIT-induced cholestasis through signaling pathway of FXR-regulated bile acid and inflammation
por: Yang, Fan, et al.
Publicado: (2016)

The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation
por: Panera, Nadia, et al.
Publicado: (2021)

KLB and NOX4 expression levels as potential blood-based transcriptional biomarkers of physical activity in children
por: Galmés, Sebastià, et al.
Publicado: (2023)

Altered Expression of Retinol Metabolism-Related Genes in an ANIT-Induced Cholestasis Rat Model
por: Takitani, Kimitaka, et al.
Publicado: (2018)

Efficient treatment of Parkinson’s disease using ultrasonography-guided rhFGF20 proteoliposomes
por: Niu, Jianlou, et al.
Publicado: (2018)

Sarcopenia is associated with osteopenia and impaired quality of life in children with genetic intrahepatic cholestatic liver disease
por: Boster, Julia M., et al.
Publicado: (2023)

iTRAQ-based quantitative proteomics analysis of the hepatoprotective effect of melatonin on ANIT-induced cholestasis in rats
por: Wang, Dingnan, et al.
Publicado: (2021)

Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2(-/-) mouse model of sclerosing cholangitis
por: Fuchs, Claudia D., et al.
Publicado: (2023)

Branched Intermediate Formation Is the Slowest Step in the Protein Splicing Reaction of the Ala1 KlbA Intein from Methanococcus jannaschii
por: Saleh, Lana, et al.
Publicado: (2011)

Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice
por: Zhao, Longwei, et al.
Publicado: (2017)

Targeted bile acid profiles reveal the liver injury amelioration of Da-Chai-Hu decoction against ANIT- and BDL-induced cholestasis
por: Zhou, YueHua, et al.
Publicado: (2022)

Naturally induced auto-anit-idiotypic antibodies. Induction by identical idiotopes in some members of an outbred rabbit family
Publicado: (1982)

Disodium gadoxetate uptake in progressive familial intrahepatic cholestasis type I: Enhancing our understanding of the cholestatic disease
por: Patel, Mikin V., et al.
Publicado: (2015)

Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases
por: Sanyal, Arun J., et al.
Publicado: (2021)

Paeonia lactiflora Pall. protects against ANIT-induced cholestasis by activating Nrf2 via PI3K/Akt signaling pathway
por: Ma, Xiao, et al.
Publicado: (2015)

Transcriptome and Gut Microbiota Profiling Analysis of ANIT-Induced Cholestasis and the Effects of Da-Huang-Xiao-Shi Decoction Intervention
por: Wang, Wang, et al.
Publicado: (2022)

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2(−/−) mice by modulating composition, signalling and excretion of faecal bile acids
por: Fuchs, Claudia Daniela, et al.
Publicado: (2018)

Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases
por: Zhao, Longwei, et al.
Publicado: (2019)

Intrahepatic Cholestasis of Pregnancy Levels of Sulfated Progesterone Metabolites Inhibit Farnesoid X Receptor Resulting in a Cholestatic Phenotype
por: Abu-Hayyeh, Shadi, et al.
Publicado: (2013)

Autoinhibition and regulation by phosphoinositides of ATP8B1, a human lipid flippase associated with intrahepatic cholestatic disorders
por: Dieudonné, Thibaud, et al.
Publicado: (2022)

FGF1 Signaling Modulates Biliary Injury and Liver Fibrosis in the Mdr2(−/−) Mouse Model of Primary Sclerosing Cholangitis
por: O’Brien, April, et al.
Publicado: (2022)

The TLR2 is activated by sporozoites and suppresses intrahepatic rodent malaria parasite development
por: Zheng, Hong, et al.
Publicado: (2015)

Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2(−/−) mouse model of sclerosing cholangitis via immunomodulatory effects
por: Fuchs, Claudia D., et al.
Publicado: (2022)

Paracrine Fibroblast Growth Factor 1 Functions as Potent Therapeutic Agent for Intrahepatic Cholestasis by Downregulating Synthesis of Bile Acid
por: Lin, Huan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1e82bsm950lr80i2q42ri1nv8g